Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 7, 2013, Pages 830-840

  Östensson, Ellinor ^a   Hellström, Ann Cathrin ^a   Hellman, Kristina ^a   Gustavsson, Inger ^b   Gyllensten, Ulf ^b   Wilander, Erik ^c   Zethraeus, Niklas ^d   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical cancer; cost effectiveness; human papillomavirus (HPV); screening; self sampling

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HEALTH CARE COSTS; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; RISK; SWEDEN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84879242205     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12143     Document Type: Article

References (56)

1. Bergstrom R, Sparen P, Adami HO,. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 1999; 81: 159-66.
2. Anttila A, Ronco G,. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer. 2009; 45: 2685-708.
3. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008; 100: 622-9.
4. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001; 84: 1616-23.
5. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009; 101: 1612-23.
6. Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikstrom I, Wilander E,. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer. 2011; 105: 694-7.
7. Sanner K, Wikstrom I, Strand A, Lindell M, Wilander E,. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer. 2009; 101: 871-4.
8. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. J Am Med Assoc. 2002; 287: 2114-9.
9. Sparen P,. Gynekologisk cellprovskontroll i Sverige-Rapport 2007. Stockholm: Karolinska Institutet, 2008.
10. Ostor AG,. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993; 12: 186-92.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD,. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338: 423-8.
12. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994; 169: 235-40.
13. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998; 132: 277-84.
14. van Oortmarssen GJ, Habbema JD,. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer. 1991; 64: 559-65.
15. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992; 327: 1272-8.
16. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S,. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol. 1992; 79 (5 Pt 1): 675-82.
17. Bearman DM, MacMillan JP, Creasman WT,. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol. 1987; 69: 151-5.
18. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995; 61: 306-11.
19. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB,. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000; 151: 1158-71.
20. Lindell M, Sanner K, Wikstrom I, Wilander E,. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. Br J Obstet Gynaecol. 2012; 119: 245-8.
21. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J,. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004; 96: 280-93.
22. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J,. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005; 99 (3 Suppl 1): S7-11.
23. Doll R, Payne P, Waterhouse JAH, (eds). Cancer incidence in five continents, Vol. I. Geneva: Union Internationale Contre le Cancer, 1966.
24. Doll R, Muir CS, Waterhouse JAH, (eds). Cancer incidence in five continents, Vol. II. Geneva: Union Internationale Contre le Cancer, 1970.
25. Waterhouse J, Muir CS, Correa P, Powell J, (eds). Cancer incidence in five continents, Vol. III. Lyon: IARC Scientific Publications No. 15, IARC, 1976.
26. Ferlay J, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR, et al. Cancer incidence in five continents, Vol. I to IX. IARC Cancer Base No. 9. Lyon, France: International Agency for Research on Cancer, 2010. Available online at: http://ci5.iarc.fr.
27. Goldie SJ, Kim JJ, Wright TC,. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619-31.
28. Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E, Gyllensten U,. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. J Clin Virol. 2009; 45: 85-9.
29. Gustavsson I, Lindell M, Wilander E, Strand A, Gyllensten U,. Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. J Clin Virol. 2009; 46: 112-6.
30. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Kehoe S, Flannelly G, Mitrou S, et al. Management of minor cervical cytological abnormalities: a systematic review and a meta-analysis of the literature. Cancer Treat Rev. 2007; 33: 514-20.
31. Benedet JL, Bender H, Jones H 3rd,. Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70: 209-62.
32. Stenstedt K, Hellstrom AC, Fridsten S, Blomqvist L,. Impact of MRI in the management and staging of cancer of the uterine cervix. Acta Oncol. 2011; 50: 420-6.
33. Ostensson E, Froberg M, Hjerpe A, Zethraeus N, Andersson S,. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. Acta Obstet Gynecol Scand. 2010; 89: 1316-25.
34. Meltzer D,. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997; 16: 33-64.
35. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C,. Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen. 2002; 99: 646-50.
36. Gold M,. Panel on cost-effectiveness in health and medicine. Med Care. 1996; 34 (12 Suppl): DS197-9.
37. Cantor SB,. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994; 14: 259-65.
38. WHO Commission on Macroeconomics and Health. Macroéconomie et santé: investir dans la santé pour le développement économique: rapport de la Commission Macroéconomie et Santé. Geneva: Organisation mondiale de la Santé, 2001.
39. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG,. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000; 20: 332-42.
40. Froberg M, Norman I, Johansson B, Hjerpe A, Weiderpass E, Andersson S,. Liquid-based cytology with HPV Triage of low-grade cytological abnormalities versus conventional cytology in cervical cancer screening. Curr Pharm Des. 2013; 19: 1406-11.
41. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604-15.
42. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. J Am Med Assoc. 2002; 287: 2372-81.
43. Kim JJ, Wright TC, Goldie SJ,. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005; 97: 888-95.
44. Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol. 2005; 193 (3 Pt 1): 650-7.
45. Sherlaw-Johnson C, Philips Z,. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer. 2004; 91: 84-91.
46. Fahey MT, Irwig L, Macaskill P,. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995; 141: 680-9.
47. Leinonen MK, Nieminen P, Lonnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. Br Med J. 2012; 345: e7789.
48. Balasubramanian A, Kulasingam SL, Baer A, Hughes JP, Myers ER, Mao C, et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis. 2010; 14: 185-95.
49. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ,. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer. 2012; 106: 1571-8.
50. Bistoletti P, Sennfalt K, Dillner J,. Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer. 2008; 122: 372-6.
51. Hellsten C, Sjostrom K, Lindqvist PG,. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. Br J Obstet Gynaecol. 2008; 115: 212-8.
52. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL,. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011; 136: 578-86.
53. van der Aa MA, Siesling S, Louwman MW, Visser O, Pukkala E, Coebergh JW,. Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989-2003. Eur J Cancer Prev. 2008; 17: 453-9.
54. Eaker S, Adami HO, Sparen P,. Reasons women do not attend screening for cervical cancer: a population-based study in Sweden. Prev Med. 2001; 32: 482-91.
55. Idestrom M, Milsom I, Andersson-Ellstrom A,. Knowledge and attitudes about the Pap-smear screening program: a population-based study of women aged 20-59 years. Acta Obstet Gynecol Scand. 2002; 81: 962-7.
56. Schiffman M,. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007; 111: 145-53.